Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Utilizing the NOTCH1 pathway in CLL treatment

Silvia Deaglio • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Silvia Deaglio, MD, PhD, University of Turin, Turin, Italy, describes the mechanisms by which NOTCH1 mutations can cause chronic lymphocytic leukemia (CLL) and the how we can target treatment with this knowledge. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Silvia Deaglio

Future advancements in the treatment of CLL 1:33
Future advancements in the treatment of CLL
Silvia Deaglio • 31 Aug 2021
Utilizing the NOTCH1 pathway in the treatment of CLL 1:37
Utilizing the NOTCH1 pathway in the treatment of CLL
Silvia Deaglio • 31 Aug 2021
The molecular and microenvironmental basis of immunodysfunction in CLL 1:44
The molecular and microenvironmental basis of immunodysfunction in CLL
Silvia Deaglio • 31 Aug 2021
The role of NOTCH signaling in CLL pathogenesis 2:11
The role of NOTCH signaling in CLL pathogenesis
Silvia Deaglio • 25 Oct 2018

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals